InflaRx (IFRX) Tax Provisions (2024 - 2025)
InflaRx (IFRX) posted Tax Provisions of $28593.6 for Q4 2025, up 299.14% sequentially from -$14358.3 in Q3 2025, and up 156.45% YoY from $11149.7 in Q4 2024.
InflaRx (IFRX) Tax Provisions (2024 - 2025) Analysis & Trends
InflaRx has reported Tax Provisions for 2 years, with the latest figure at $28593.6 in Q4 2025.
- Quarterly Tax Provisions rose 156.45% year-over-year to $28593.6 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19655.5 (up 262.63% YoY) and the FY2025 annual result came in at $13876.3, up 145.75% from the prior year.
- Tax Provisions grew to $28593.6 in Q4 2025 per IFRX's latest filing, from -$14358.3 in the prior quarter.
- Over five years, Tax Provisions peaked at $28593.6 in Q4 2025 and troughed at -$14358.3 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.31 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.90 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -90.33 Mn |
| 10 | InflaRx | 135.25 Mn | -49.00 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28,593.56 |
| Sep 30, 2025 | -14,358.33 |
| Dec 31, 2024 | 11,149.72 |
| Sep 30, 2024 | -5,729.41 |